• 16 December 2019: OIA response: Lamotrigine NPPA change

• 11 December 2019: OIA response: MMR vaccine stock

• 10 December 2019: OIA response: Antifungals data

• 10 December 2018: OIA response: 2018-12-12 Research projects

• 12 December 2019: OIA response: Adalimumab data

• 9 December 2019: OIA response: Lamotrigine brand change

• 5 December 2019: OIA response: Sildenafil

• 4 December 2019: OIA response: Statins prices

• 4 December 2019: OIA response: Lamotrigine NPPA data

• 28 November 2019: OIA response: Lamotrigine contingency plan activation

• 28 November 2019: OIA response: Male sex change hormones data

• 27 November 2019: OIA response: Asthma inhalers data

• 26 November 2019: OIA response: Fingolimod data

• 25 November 2019: OIA response: Pembrolizumab and nivolumab

• 25 November 2019: OIA response: Funded mental health drugs

• 21 November 2019: OIA response: Cefuroxime data

• 20 November 2019: OIA response: Pembrolizumab and nivolumab data, July to September 2019

• 19 November 2019: OIA response: Meningitis vaccines communications

• 14 November 2019: OIA response: Prescription numbers

• 12 November 2019: OIA response on MMR vaccine

• 31 October 2019: OIA Response: 2019-20 budget bid letter

• 29 October 2019: OIA response: Venlafaxine and lamotrigine NPPA data

• 24 October 2019: OIA response: Chloramphenicol data

• 24 October 2019: OIA response: Anti-VEGF treatment

• 24 October 2019: OIA response: Compassionate supply response

• 16 October 2019: Asthma inhalers

• 15 October 2019: OIA Response: Opioid substitution

• 1 October 2019: OIA response: Lamotrigine safety

• 26 September 2019: OIA response: Growth hormone data

• 25 September 2019: OIA response: Venlafaxine brand use data

• 18 September 2019: OIA response: Phenelzine supply

• 17 September 2019: OIA response: Leuprorelin and goserelin data

• 12 September 2019: OIA response: Psychometric testing

• 1 August 2019: OIA response: Pembrolizumab and nivolumab data

• 22 July 2019: OIA Response: Pfizer PHARMAC communications

• 19 July 2019: OIA Response: Asthma and Respiratory Foundation payments

• 16 July 2019: OIA Response: University of Auckland communications

• 5 July 2019: OIA Response: Keith Petrie communications

• 26 June 2019: OIA Response: Venlafaxine brand change data

• 20 June 2019: OIA Response: Meningococcal vaccine meetings

• 18 June 2019: OIA Response: Infliximab hospital purchase data

• 18 June 2019: OIA Response: Adalimumab and etanercept data

• 11 June 2019: OIA Response: MSTAC Minutes

• 11 June 2019: OIA Response: Adalimumab, etanercept, infliximab and secukinumab data

• 10 June 2019: OIA Response: Mesalazine data

• 10 June 2019: OIA Response: Compounding data for antiepileptics

• 30 May 2019: OIA Response: Pharmaceutical budget bid and final budgets

• 29 May 2019: OIA Response: Insulin needles and syringes data

• 23 May 2019: OIA Response: Pharmaceutical budget bid

• 22 May 2019: OIA Response: Pertuzumab renewals data

• 20 May 2019: OIA Response: Venlafaxine brand change roll out plan

• 15 May 2019: OIA Response: Lamotrigine correspondence

• 15 May 2019: OIA Response: Meningococcal W and Scout Jamboree

• 13 May 2019: OIA Response: Pembrolizumab criteria

• 9 May 2019: OIA Response: Vaccine costs

• 30 April 2019: OIA Response: Daivobet gel dispensing data

• 26 April 2019: OIA Response: PrEP Data

• 24 April 2019: OIA Response: Parental leave policies

• 16 April 2019: OIA Response: Antiepileptic medicines data

• 15 April 2019: OIA Response: Adrenaline autoinjector cost utility analysis

• 8 April 2019: OIA response: Sleeping medicines data

• 01 April 2019: OIA Response: Erlotinib and other medicines data

• 13 March 2019: OIA Response: Summary of factors determining CPB expenditure

• 27 February 2019: OIA Response: Pembrolizumab and nivolumab data

• 26 February 2019: OIA Response: Drug shortages

• 8 February 2019: OIA Response: Waitangi Tribunal research report

• 29 January 2019: OIA Response: Zytiga data

• 14 January 2019: OIA response: Technology Assessment Reports for pembrolizumab in advanced melanoma